Revolution Medicines (RVMD) Gains from Sales and Divestitures (2020 - 2026)
Revolution Medicines' quarterly Gains from Sales and Divestitures came in at $367871.0 in Q1 2026, up 35.48% year-on-year from $271536.0 in Q1 2025, and down 72.74% quarter-over-quarter from $1.3 million in Q4 2025.
Revolution Medicines has reported Gains from Sales and Divestitures for 7 years, with the latest figure at $367871.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 35.48% year-over-year to $367871.0; the trailing twelve-month figure through Mar 2026 stood at $367871.0 (up 35.48% YoY), and the FY2025 full-year result was $1.3 million, up 33.43% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $367871.0, down from $1.3 million in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $1.3 million in Q4 2025, with the low at $26931.0 in Q1 2022.
- Average Gains from Sales and Divestitures over 5 years is $466786.6, with a median of $367871.0 recorded in 2026.
- Year-over-year, Gains from Sales and Divestitures jumped 1397.83% in 2022 and soared 33.43% in 2025.
- Tracing RVMD's Gains from Sales and Divestitures over 5 years: stood at $278848.0 in 2022, then soared by 106.91% to $576974.0 in 2023, then jumped by 75.27% to $1.0 million in 2024, then surged by 33.43% to $1.3 million in 2025, then tumbled by 72.74% to $367871.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $367871.0 (Q1 2026), $1.3 million (Q4 2025), and $978467.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 367,871.00 |
| Mar 31, 2026 | 367,871.00 |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 978,467.00 |
| Sep 30, 2025 | 978,467.00 |
| Jun 30, 2025 | 633,511.00 |
| Jun 30, 2025 | 633,511.00 |
| Mar 31, 2025 | 271,536.00 |
| Mar 31, 2025 | 271,536.00 |
| Dec 31, 2024 | 1.01 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 724,965.00 |
| Sep 30, 2024 | 724,965.00 |
| Jun 30, 2024 | 469,031.00 |
| Jun 30, 2024 | 469,031.00 |
| Mar 31, 2024 | 165,078.00 |
| Mar 31, 2024 | 165,078.00 |
| Dec 31, 2023 | 576,974.00 |
| Dec 31, 2023 | 576,974.00 |
| Sep 30, 2023 | 420,209.00 |
| Sep 30, 2023 | 420,209.00 |
| Jun 30, 2023 | 260,143.00 |
| Jun 30, 2023 | 260,143.00 |
| Mar 31, 2023 | 85,891.00 |
| Mar 31, 2023 | 85,891.00 |
| Dec 31, 2022 | 278,848.00 |
| Dec 31, 2022 | 278,848.00 |
| Sep 30, 2022 | 194,052.00 |
| Sep 30, 2022 | 194,052.00 |
| Jun 30, 2022 | 121,319.00 |
| Jun 30, 2022 | 121,319.00 |
| Mar 31, 2022 | 26,931.00 |
| Mar 31, 2022 | 26,931.00 |
| Dec 31, 2021 | 78,010.00 |
| Dec 31, 2021 | 78,010.00 |
| Sep 30, 2021 | 52,619.00 |
| Sep 30, 2021 | 52,619.00 |
| Jun 30, 2021 | 32,615.00 |
| Jun 30, 2021 | 32,615.00 |
| Mar 31, 2021 | 1,798.00 |
| Mar 31, 2021 | 1,798.00 |
| Dec 31, 2020 | 1,681.00 |
| Dec 31, 2020 | 1,681.00 |